Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Aging Clinical Trials

A listing of Aging medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (882) clinical trials

Early Intervention in Cognitive Aging

Late-onset AD develops over many years during a preclinical period in which neuropathological changes accumulate before dementia is evident. Deposition of amyloid-beta (A) in the brain is the earliest recognized biomarker of AD pathology, and, demographically, A accumulation begins to accelerate at age 50, a period when the incidence of ...

Phase N/A

A Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam Subjects (>=16 to 80 Years of Age) With Epilepsy

The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial seizures with or without secondary generalization despite current treatment with 1 or 2 concomitant antiepileptic drugs (AEDs) and to assess ...


Healthy Aging Resources to Thrive (HART)

Healthy Aging Resources to Thrive (HART) is a two-stage randomized controlled trial (RCT) of adults over age 60 with obesity to determine the efficacy of a novel sitting-reduction intervention and its impact on cardiometabolic risk markers. Participants will be randomized to a 6-month sitting reduction intervention (termed I-STAND) or healthy-living ...

Phase N/A

Global Atrophie Biomarker Evaluation Study (GABiE)

To investigate the use of microperimetry and SS-OCT in assessing the natural changes of retinal sensitivity and anatomy in the perilesional zone of geographic atrophy areas in patients with dry age-related macular degeneration.

Phase N/A

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Study duration per participant is approximately 82 weeks, including an up to 6-week screening period, 52-week treatment period, and 24-week follow-up period.


Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation

Objective: The objective of this study is to investigate the potential efficacy of vitamin A palmitate in improving dark adaptation in participants with age-related macular degeneration (AMD) and abnormal dark adaptation. Study Population: Ten participants will be initially accrued, however, up to twenty participants with AMD who meet the eligibility ...

Phase N/A

Dose-response Effect of Dietary Nitrate on Muscle Function in Older Individuals

This study consists of four visits that will take a minimum of 15 days to complete. Study Visit One (Screening) 1-2 hours The purpose of the screening visit is to explain all aspects of the study. The investigators will also determine if individuals can participate in the study. Eligible subjects ...


Decision Making and Implementation of Aging-in-Place/Long Term Care Plans Among Older Adults

Subjects who are part of the NIA-funded LitCog study will be given access to, a web-based decision-making and planning tool. Participants will be followed for up to 42 months to examine the mediating/moderating factors involved in decision-making, timing of decision implementation, and goal concordance. Findings have the potential to ...

Phase N/A

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

The primary objective for this study is to assess the safety and tolerability as well as preliminary efficacy of venetoclax in combination with cobimetinib, and venetoclax in combination with idasanutlin in patients >/= 60 years of age with relapsed or refractory acute myeloid leukemia (R/R) AML who are not eligible ...


Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

The purpose of this Phase 1, multicenter, open-label study is to determine the maximum tolerated dose (MTD) of AG-270, administered as a single agent or in combination with taxane-based chemotherapy, and to characterize its dose-limiting toxicities (DLTs) when given daily by mouth to participants with advanced solid tumors or lymphoma ...